Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
复制标题
DOI：
10.1080/2162402x.2016.1231292
复制
发表时间：
2016-01-01
期刊：
影响因子：
7.2
通讯作者：
Flatz, Lukas
中科院分区：
文献类型：
--
作者：
Ali, Omar Hasan;Diem, Stefan;Flatz, Lukas
免疫检查点抑制剂已经导致癌症患者的治疗显著改善。经常观察到自身免疫副作用，包括皮肤反应。在黑色素瘤中，这些包括皮疹和白癜风，并被证明与延长的总生存期有关。人们对非小细胞肺癌（NSCLC）患者在免疫治疗期间的皮肤反应知之甚少。在这里，我们回顾性研究了40例接受抗PD-1抗体nivolumab治疗的转移性NSCLC患者的免疫相关不良皮肤反应（irAE）。40例患者中有7例（17%）发生irAE。与27例非应答者中的2例（7%）相比，12例应答者中的5例（42%）皮肤irAE与肿瘤应答相关。组织学上，鳞屑斑块显示主要由淋巴细胞组成的皮炎。我们观察到nivolumab治疗的NSCLC患者的皮肤irAE与肿瘤缓解之间呈正相关。淋巴细胞皮肤浸润的模式根据组织学肿瘤亚型（腺癌与鳞状细胞癌NSCLC）而不同。
Immune checkpoint inhibitors have led to considerable therapy improvement in cancer patients. Autoimmune side effects including skin reactions are frequently observed. In melanoma, those include rash and vitiligo and were shown to be associated with a prolonged overall survival. Little is known about skin reactions in non-small cell lung cancer (NSCLC) patients during immunotherapy. Here, we retrospectively investigated immune-related adverse skin reactions (irAEs) in 40 patients with metastatic NSCLC treated with the anti-PD-1 antibody nivolumab. 7 out of 40 patients (17%) developed an irAEs. Skin irAEs correlated with tumor responses in 5 of 12 responders (42%) as compared to 2 of 27 non-responders (7%). Histologically, scaly plaques showed dermatitis consisting mainly of lymphocytes. We observed a positive correlation between skin irAEs and tumor responses in patients with NSCLC treated with nivolumab. Patterns of lymphocytic skin infiltration differed depending on the histological tumor subtype (adenocarcinoma versus squamous cell carcinoma NSCLC).